U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905327) titled 'A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects' on March 25.
Brief Summary: This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.
Study Start Date: March 08, 2023
Study Type: INTERVENTIONAL
Condition:
Mild Hypertension
Intervention:
DRUG: QCZ484
doses of 50, 150, 300 or 600 mg via subcutaneous injection
DRUG: Placebo
via subcutaneous injection
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Novartis Pharmaceuticals
Published by HT Digital Content Service...